Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

PALO ALTO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced oral, poster presentations, and symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek conference in Las Vegas, NV on September 3-5, 2024.

Key highlights of the ZTlido (lidocaine topical system) 1.8% presentation:

• September 4, 2024 (Wednesday)
  • NON-CME Presentation in the Castellana Ballroom.
  • 12:00PM PT - 1:00PM PT
  • TITLE: What to do when pain relief with Gabapentinoids isn’t enough?
  • SPEAKER: Dr. Charles Argoff
  • DESCRIPTION: Gabapentinoids (gabapentin and pregabalin) are the foundational analgesics used to treat neuropathic pain of PHN, and their usage has grown rapidly in recent years given increasing scrutiny around opioid prescribing. The unmet need, though, remains high, given the challenges with titrating them to an effective dose. Dr Charles Argoff will review what analgesic options exist to optimize gabapentinoids, and the trade-offs that come with different agents. Dr. Argoff is Professor of Neurology and Director of the Comprehensive Pain Program at Albany Medical Center in New York. He is an internationally renowned for his work in Pain Management - in research, teaching and patient care, and serves as the President of AAPM (American Academy of Pain Management).
• September 5, 2024 (Thursday)
  • 5:50PM PT – 6:00PM PT: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis to be Presented by Srinivas Nalamachu, M.D.
  • 6:05PM PT – 6:15PM PT: Decreased Cost Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis to be Presented by Srinivas Nalamachu, M.D.
    

For more information on Scilex Holding Company, refer to www.scilexholding.com.

For more information on Scilex Holding Company Sustainability Report, refer to www.scilexholding.com/investors/sustainability.

For more information on ZTlido including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB, including Full Prescribing Information, refer to www.elyxyb.com.